. Regulation of atrial contraction by PKA and PKC during development and regression of eccentric cardiac hypertrophy. Am J Physiol Heart Circ Physiol 288: H695-H704, 2005. First published October 14, 2004; doi:10.1152/ajpheart.00783.2004.-ANG II plays a major role in development of cardiac hypertrophy through its AT1 receptor subtype, whereas angiotensin-converting enzyme (ACE) inhibitors are effective in reversing effects of ANG II on the heart. The objective of this study was to investigate the role of PKA and PKC in the contractile response of atrial tissue during development and ACE inhibitor-induced regression of eccentric hypertrophy induced by aortocaval shunt. At 1 wk after surgery, sham and shunt rats were divided into captopril-treated and untreated groups for 2 wk. Then isometric contraction was assessed by electrical stimulation of isolated rat left atrial preparations superfused with Tyrode solution in the presence or absence of specific inhibitors KT-5720 (for PKA) and Ro-32-0432 (for PKC) and high Ca 2ϩ . Peak tension developed was greater in shunt than in sham hearts. However, when expressed relative to tissue mass, hypertrophied muscle showed weaker contraction than muscle from sham rats. In sham rats, peak tension developed was more affected by PKC than by PKA inhibition, whereas this differential effect was reduced in the hypertrophied heart. Treatment of shunt rats with captopril regressed left atrial hypertrophy by 67% and restored PKC-PKA differential responsiveness toward sham levels. In the hypertrophied left atria, there was an increase in the velocity of contraction and relaxation that was not evident when expressed in specific relative terms. Treatment with ACE inhibitor increased the specific velocity of contraction, as well as its PKC sensitivity, in shunt rats. We conclude that ACE inhibition during eccentric cardiac hypertrophy produces a negative trophic and a positive inotropic effect, mainly through a PKC-dependent mechanism.
pertrophy, possess inotropic properties and have been shown to modulate the contractile activity of the heart, irrespective of their hypertrophic effects. The pathological role of ANG II during eccentric cardiac hypertrophy has been determined through reversal of the associated hemodynamic changes by an AT 1 receptor antagonist (37) . Moreover, it seems that local ANG II plays a more important role than circulating ANG II in development of cardiac hypertrophy (20) . Aortocaval shunt has been shown to produce substantial volume overload and to increase absolute and relative heart weights, with the greatest effect being in the atria (3, 17) . These changes are paralleled by a corresponding elevation in the levels of cardiac angiotensin-converting enzyme (ACE) mRNA (25) , atrial AT 1 mRNA expression (3) , and atrial collagen I and II levels (23) . ACE inhibitors have proven to be potent and effective agents in preventing and regressing the cardiac hypertrophy during volume and pressure overload (14, 17, 21, 40) .
On the other hand, AT 1 receptor subtype is positively coupled to phospholipase C and negatively coupled to adenylate cyclase. Early during development of eccentric cardiac hypertrophy, PKA activity was elevated and correlated with the force-generating capacity of the heart (24), which is greatly influenced by intracellular Ca 2ϩ homeostasis. Recently, it was reported that ANG II augmented cAMP formation by Ca 2ϩ -dependent activation of adenylate cyclase (28) . On the other hand, binding of ANG II to AT 1 receptors has been shown to activate the Ca 2ϩ -dependent PKC (for review see Ref. 39) . It has been demonstrated that ANG II induces an increase in inositol phosphate production that was mediated through tyrosine phosphorylation (13) . Accordingly, the expression of PKC-␣ mRNA was elevated with cardiac hypertrophy and suppressed after regression of cardiac hypertrophy with ACE inhibitor treatment (22) . The PKA and PKC signaling pathways are Ca 2ϩ dependent and have been shown to regulate Ca 2ϩ homeostasis in the heart (16, 31, 35, 44) , which would affect myocardial contractility.
Knowing that during eccentric cardiac hypertrophy the atria play an important role in ventricular filling and the renin-angiotensin system affects myocardial contractility through ANG II-dependent signaling, we hypothesize that PKA and PKC play a crucial role in defining the force of contraction of the atrium. Thus the present study was designed specifically to investigate the role of PKA and PKC in the contractile response of atrial tissue during the development and the ACE inhibitor-induced regression of eccentric hypertrophy.
MATERIALS AND METHODS

Experimental Animals and Groups
All protocols and animal care were approved and performed according to the Institutional Animal Care and Use Committee at Howard University. Adult male Sprague-Dawley Rats (300 Ϯ 85 g body wt; Charles Rivers Breeding Laboratories, Wilmington, MA) were housed in a temperature-controlled room with a 12:12-h lightdark cycle and fed a standard chow diet throughout their stay in the Animal Section of the College of Medicine.
Animals were separated into two groups: sham-operated rats [control (sham) group] and aortocaval shunt-induced eccentric hypertrophy rats [experimental (shunt) group]. At 1 wk after the surgery, each group was divided into captopril-treated and untreated groups to allow the development of eccentric cardiac hypertrophy. Captopril was administered to the treated groups in the drinking water at 500 mg ⅐ l Ϫ1 ⅐ day Ϫ1 for 2 wk to assess regression of cardiac hypertrophy by ACE inhibitors. The sham and shunt rats drank similar amounts of water during the 2-wk treatment period: 38.73 Ϯ 5.96 and 39.61 Ϯ 5.31 ml/day, respectively. With 500 mg/ml captopril, this breaks down to captopril intake of 19.80 and 19.36 mg/day, respectively.
Surgical Procedure
The aortocaval shunt was produced by the method described by Garcia and Diebold (12) . Briefly, rats were anesthetized with pentobarbital sodium (50 mg/kg ip), and a midline incision was made to expose the abdominal aorta and vena cava. A bulldog vascular clamp was placed across the aorta, proximal to the area of the puncture. The aorta was punctured with a disposable 18-gauge needle, and the common wall between the aorta and inferior vena cava was grasped through the incision, creating a fistula between the two vessels below the renal arteries. The needle was withdrawn and sealed with a drop of cyanoacrylate glue. The abdominal incision was sutured with Biosyn monofilament synthetic absorbable sutures. The shunts were produced under sterile surgical conditions. Sham-operated rats, serving as the control, underwent the same surgical procedure, except the aorta and inferior vena cava were not punctured. Immediately after the procedure, the animals were given 1 ml of sterile saline to prevent dehydration from any blood loss and allowed to recover from surgery in warmed conditions.
Hemodynamic Measurements
Blood pressure measurements were recorded to rule out the development of hypertension and possible development of high-pressure concentric hypertrophy as well as the effects of captopril in the treated groups. Systolic blood pressure was measured by the tail-cuff method without anesthesia. Animals were placed in a specialized rat restrainer, and blood pressure was measured using a rat tail blood pressure system (model RTBP1001, Kent Scientific, Litchfield, CT) and recorded by a digital oscilloscope (model 310, Nicolet) for subsequent analysis. Blood pressures and body weights were recorded in sham and shunt rats 1, 5, 9, 13, 17, and 21 days after the surgery.
At the end of all experiments, wet weights of the heart chambers and total heart weight were recorded to assess the level of cardiac hypertrophy by measuring the heart weight-to-body weight ratio for the sham and shunt groups.
Multicellular Preparation Setup and Experimental Procedure
Tissue isolation and recording. Animals were killed by decapitation under pentobarbital sodium sedation (50 mg/kg ip). The left atrial muscle was isolated and mounted vertically in a Radnoti tissue organ bath system, with one end attached to the organ bearer with field stimulation electrodes and the other end attached to an isometric force transducer (model FTO3, Grass, Quincy, MA). The transducer was mounted on a micromanipulator, so that fine steps to adjust the resting tension could elongate the muscle. All experiments were carried out at 1 g of resting tension. The force transducer was connected to a amplifier (model 7P1G, Grass) and a data-recording system (model 79E, Grass) to record the tension developed. The signal was fed simultaneously into a differentiator amplifier (model 7P20C, Grass) to record the first derivatives of the active tension developed. The two signals were fed into a digital oscilloscope (model 310, Nicolet) and stored on disk for analysis.
Preparations were stimulated via electrical field stimulation at a basic frequency of 0.75 Hz at 1.5 times threshold voltage and stimulus duration of 3.5 ms. At this frequency, preparations can be studied for long periods (3-4 h) without noticeable deterioration.
Multicellular contraction studies. The isolated preparation was superfused in the tissue bath with Tyrode solution (in mM: 137 NaCl, 5.4 KCl, 2.7 CaCl 2, 0.5 MgCl2, 11.9 NaHCO3, 0.45 NaH2PO4, and 5.55 glucose) at 5 ml/min. The superfusate was continuously aerated with 95% O 2-5% CO2, and pH was adjusted to 7.4 Ϯ 0.03 with NaOH or HCl. Temperature was kept constant at 31 Ϯ 0.5°C in the tissue bath by means of a thermostatically controlled water jacket surrounding the tissue bath.
At the start of the experimental procedure, the muscular preparations were left to equilibrate to a steady state for 60 min or until the resting tension remained constant. At the end of the equilibration period, control contractions were recorded. The superfusate was then changed sequentially to Tyrode solution supplemented with PKA inhibitor (KT-5720, 10 Ϫ7 M), high Ca 2ϩ (5.14 mM), normal Tyrode solution, PKC inhibitor (Ro-32-0432, 10 Ϫ7 M), high Ca 2ϩ (5.14 mM), and then normal Tyrode solution. The peak tension developed (PTD) and first derivatives of contraction and relaxation were recorded after 5, 10, and 15 min in each solution.
KT-5720 (Calbiochem, San Francisco, CA) is a potent specific cell-permeable inhibitor of PKA. It does not significantly affect the activity of other protein kinases, especially PKC, PKG, and myosin light chain kinase. Therefore, KT-5720 was chosen to study the effect of PKA inhibition in cardiac tissue. Ro-32-0432 (Calbiochem) is a selective cell-permeable PKC inhibitor. It is even highly selective for the Ca 2ϩ -dependent PKC isoforms (e.g., PKC-␣ and PKC-␤) over the Ca 2ϩ -independent PKC isoforms (e.g., PKC-␦ and PKC-⑀). The PKC isoforms inhibited by Ro-32-0432 have been implicated in various models of cardiac hypertrophy, with the Ca 2ϩ -dependent isoforms showing a greater association with contractile function of the heart. Thus this PKC inhibitor seems to be the best choice for determining PKC alterations of inotropic activity during cardiac hypertrophy.
Statistical Methods
Values are means Ϯ SE. All statistical analysis was performed using SigmaStat software and verified using Microsoft Excel and Prism software, which gave the same result. Paired Student's t-test was used to compare data before and after drug treatment of the same animal group. Because the inhibitors' effects were not tested in a cumulative manner but, rather, an equilibrium control period (Tyrode) preceded the addition of each inhibitor, one-way ANOVA was used for significance when the effects of one drug were compared in two different animal groups among the four groups of animals: sham (control), shunt (hypertrophy), sham ϩ captopril (experimental control), and shunt ϩ captopril (regression). Furthermore, there were no statistical differences between the equilibrium periods tested in one protocol. Statistical significance was assumed for P Յ 0.05. Figure 1 shows the blood pressure profile of sham and shunt groups during the 3 wk after surgery in the presence and absence of the ACE inhibitor captopril. At 3 wk after surgery, there was no significant difference in the blood pressure profile between the untreated and treated sham (106.0 Ϯ 2.5 and 101.8 Ϯ 3.1 mmHg, respectively) and shunt (109.2 Ϯ 1.1 and 110.0 Ϯ 4.3 mmHg, respectively) groups. 
RESULTS
Physiological Parameters Before and After ACE Inhibitor Treatment
Left Atrial Contraction During Development of Eccentric Hypertrophy
Modulation of left atrial PTD of sham and shunt rats by PKA, PKC, and high Ca 2ϩ is presented in Fig. 2 . In the left atrium of sham-operated rats, peak tension induced by electrical stimulation ( Fig. 2A) . Relative left atrial weight is a measure of the level of left atrial hypertrophy. During cardiac hypertrophy, muscular dysfunction at the unit level may be mitigated by increased muscle mass, whereby normalization would definitely unveil its proper functional state. Thus, expressing the PTD in relation to the relative left atrial weight is a measurement of the specific PTD value, which is independent of the degree of tissue mass. In that sense, specific PTD is an interesting approach when inotropy of shunt and sham rats is compared. Accordingly, in control conditions (Fig. 2B) (Fig. 2D) was not significantly different between sham and shunt rats.
Left Atrial Velocity of Contraction During Development of Eccentric Hypertrophy
Modulation of left atrial velocity of contraction (ϩdT/dt) of sham and shunt rats by PKA, PKC, and high Ca 2ϩ is presented in Fig. 3 . In sham rats, ϩdT/dt of the left atrium was not significantly affected by PKA inhibition (Fig. 3A) ). This may indicate that factors that affect ϩdT/dt at the myofibrillar level may not be challenged in the shunt animals, although the eccentric hypertrophy of the heart is producing a higher ϩdT/dt at the tissue level. Figure 3C shows the percent change in ϩdT/dt of the left atrium due to PKA inhibitor (10 Ϫ7 M) and PKC inhibitor (10 Ϫ7 M) in sham and shunt rats. PKA inhibition produced a similar percent reduction in both groups. However, PKC inhibition was significantly more effective than PKA inhibition in reducing ϩdT/dt in shunt rats (P Ͻ 0.05), but not in sham rats. The percent change in ϩdT/dt induced by elevation of extracellular Ca 2ϩ (Fig. 3D) was not significantly different between sham and shunt rats.
Left Atrial ϪdT/dt During Development of Eccentric Hypertrophy
Modulation of left atrial velocity of relaxation (ϪdT/dt) of sham and shunt rats by PKA, PKC, and high Ca 2ϩ is presented in Fig. 4 . PKA inhibition reduced ϪdT/dt of the left atrium (Fig. 4A) (Fig. 4D) .
Changes in Left Atrial Contraction After Regression of Eccentric Hypertrophy by ACE Inhibitor
Inhibition of ACE reduces circulating as well as local tissue ANG II concentrations, which attenuates the activation of ANG II-dependent signaling pathways, such as those related to PKA and PKC. Thus modulation of the inotropic activity by these second messengers would depend on their relative contribution to muscular contractility. Figure 5 shows that treatment of shunt rats with ACE inhibitor improved their specific PTD to a level comparable to that of the untreated sham control rats (61.31 Ϯ 9.91 and 49.56 Ϯ 3.84 mg/relative left atrial wt, respectively), which is greater than that of the shunt rats (38.42 Ϯ 5.82, P Ͻ 0.05). In addition and similar to the untreated sham rats, captopril-treated shunt rats showed an enhanced response to elevated extracellular Ca 2ϩ with respect to the untreated shunts (P Ͻ 0.05). Interestingly, this improved contractility in the captopril-treated hypertrophied hearts was associated with a restoration of the differential influence of PKA and PKC on PTD (2.78 Ϯ 0.04 and 22.42 Ϯ 0.07% for PKA and PKC, respectively, P Ͻ 0.01), as in control untreated sham rats. On the other hand, there was no significant difference in the effects of PKA and PKC inhibition or high extracellular Ca 2ϩ on PTD between treated and untreated sham rat hearts.
Changes in Left Atrial ϩdT/dt and ϪdT/dt After Regression of Eccentric Hypertrophy by ACE Inhibitor
With respect to the untreated shunt-operated rats, captopril treatment significantly improved the specific ϩdT/dt by 37.41 Ϯ 2.58% (P Ͻ 0.01) and its response to elevated extracellular Ca 2ϩ by 46.67% Ϯ 2.88 (P Ͻ 0.01) in shunt rat hearts (Fig. 6 ). In addition, ϩdT/dt was reduced by PKC inhibition (20.87 Ϯ 0.04%, P Ͻ 0.05) but not by PKA inhibition in the captopril-treated shunt rat hearts.
On the other hand, captopril treatment increased the specific ϪdT/dt by 63.64 Ϯ 2.23% (P Ͻ 0.01) and its response to elevated extracellular Ca 2ϩ by 71.52 Ϯ 2.22% (P Ͻ 0.01) of shunt rat hearts (Fig. 7) . This increase in specific ϪdT/dt was significantly reduced (41.34 Ϯ 0.01%, P Ͻ 0.01) by PKC, but not PKA, inhibition.
In addition, there was no significant difference in the effects of PKA and PKC inhibitor or high extracellular Ca 2ϩ on ϩdT/dt or ϪdT/dt between treated and untreated sham rat hearts.
DISCUSSION
In the present study, we have found that 2 wk of treatment with captopril prevented the development of eccentric cardiac hypertrophy by 80%, whereas the left atrial and ventricular hypertrophy regressed by 80 and 50%, respectively. This represents a regression from a moderate to a low level of cardiac hypertrophy (27) . Similar findings were reported previously showing regression of eccentric hypertrophy by ACE inhibitors (17, 34) , specifically in the atria. The aortocaval shunt did not induce a change in the systolic blood pressure, which was not affected by captopril treatment. In the sham rats, left atrial PTD was significantly more affected by PKC than by PKA inhibition. At the same concentration, PKC inhibition produced a greater response than PKA inhibition in the sham rats; this difference in the atrial response to protein kinase inhibitors was significantly reduced in rats with aortocaval shunt. In addition, the force of contraction produced by the hypertrophied left atrium was greater than that of the shamoperated controls. In contrast, the specific tension developed per relative left atrial weight was significantly weaker in the hypertrophied than in the sham control, in agreement with reduced contraction amplitude at the level of the myofiber (26) . In the atrial tissue, elevation of subsarcolemmal Ca 2ϩ by influx of Ca 2ϩ through the slow Ca 2ϩ channels (I Ca,L ) establishes the cytosolic Ca 2ϩ gradient necessary to initiate the regenerative and propagating Ca 2ϩ -induced Ca 2ϩ release from nonjunctional sarcoplasmic reticulum to generate a contraction (26, 33) . Effectively, at high Ca 2ϩ , the specific PTD by the hypertrophied left atrium tended to be weaker than that by the sham controls. Therefore, these data may indicate a functional inotropic defect at the basic contractile unit (myofiber) level in shunt rats that is compensated for by the hypertrophy of the heart tissue to maintain a normal cardiac function (compensated phase). Treatment with ACE inhibitor effectively reduced the aortocaval shunt-induced structural changes and restored the differential in protein kinase influence on contractility. The tension developed in the captopril-treated shuntoperated rat hearts reverted to a predominantly PKC-dependent process, as in the sham hearts. Thus the ACE inhibitor showed opposite, but disproportionate, effects on the PKA-and PKCinduced inotropic activity of the eccentric hypertrophied heart, with significant enhancement of the latter. Concurrently, captopril treatment restored the strength of the specific PTD in the shunt hearts to levels in the sham hearts, under normal as well as elevated extracellular Ca 2ϩ . This may suggest that treatment of eccentric cardiac hypertrophy with ACE inhibitor improves the inotropic activity of the left atrium mainly through a Ca 2ϩ -dependent PKC mechanism. The effect of ACE inhibitors on PKC is still controversial because of differences in species or model used and various experimental designs (1, 4, 36) . Nevertheless, it has been shown that chronic captopril treatment increases PKC activity in the rat (1, 45) , which may improve myocardial contractility and intracellular Ca 2ϩ transients (2, 30) . On the other hand, it has been shown that treatment with ACE inhibitor does not significantly affect PKA level or activity in the heart (7, 19, 29) , which is consistent with our findings.
In the hypertrophied left atria, there is an increase in the ϩdT/dt and ϪdT/dt that was not evident when expressed in specific relative terms. Treatment with ACE inhibitor increased the specific ϩdT/dt in the shunt-operated rat heart. In addition, our data show that, in contrast to the sham heart, the left atrial ϩdT/dt in the hypertrophied heart is mainly PKC sensitive. Captopril treatment of shunt-operated rats increased the atrial ϩdT/dt along with its PKC sensitivity. Therefore, the increase in ϩdT/dt in the hypertrophied left atrial muscle seems to be mediated mainly through a PKC-dependent mechanism. This observation is consistent with earlier findings that PKC improves myofilament Ca 2ϩ sensitivity (41) , decreases the Ca 2ϩ requirement of the contractile machinery (31) , and increases activation of the slow Ca 2ϩ channels, which are main determinants of ϩdT/dt (2, 35). Furthermore, it has been reported that ACE inhibitor treatment increases junctional conductance through activation of PKC (10), but not PKA (9) , suggesting an improved contractility due to enhanced synchronization and excitation-contraction coupling of the myocardial tissue. On the other hand, ϪdT/dt shows a stronger dependency on PKC than on PKA in both groups, which was more significant in the hypertrophied heart. ACE inhibitor treatment improved ϪdT/dt and its PKC, but not PKA, sensitivity. This is in agreement with the recent findings (43) showing an increase in the relaxation rate of the adult rat myocytes through a PKCdependent phosphorylation of troponin I, which is conducive for an increase in the rate of Ca 2ϩ dissociation from the myofilament.
The change in protein kinase dependence of ϩdT/dt is consistent with a major role of the PKC-dependent signaling transduction during eccentric hypertrophy. In addition, it has been shown that the ventricular myosin light chain subunit isoforms VLC1 and VLC2 are ectopically reexpressed and ␣-myosin heavy chain becomes largely replaced by ␤-myosin heavy chain in atrial tissue from volume-overloaded hearts. PKC, but not PKA, phosphorylates VLC to increase the Ca 2ϩ sensitivity of force development and ATPase activity (32) . This may translate into an increased ϩdT/dt and ϪdT/dt of the hypertrophied heart.
The aim of this study is to assess the contribution of PKA and PKC, and not the different subtypes, to atrial contraction; however, recent work by others lends additional support to our data. Accordingly, one PKC isoform has been shown to be involved in regulating cardiac contractility. Adenoviral-mediated expression of wild-type PKC-␣, but not PKC-␤, PKC-␦, PKC-⑀, or PKC-, induced cardiac hypertrophy characterized by increased cell surface area, increased protein synthesis, and increased expression of atrial natriuretic factor. In agreement with our data using Ro-32-0432 as a selective Ca 2ϩ -dependent PKC inhibitor, experiments with dominant-negative forms of PKC isozymes revealed a necessary role for PKC-␣ as a mediator of agonist-induced cardiac hypertrophy. More recently, observations with PKC-␣ knockout and transgenic mice suggest that PKC-␣ is a fundamental regulator of cardiac contractility and Ca 2ϩ handling. Modulation of PKC-␣ activity affects dephosphorylation of phospholamban and alters sarcoplasmic reticulum Ca 2ϩ loading and the Ca 2ϩ transient. Mechanistically, PKC-␣ directly phosphorylates protein phosphatase inhibitor-1, altering the activity of protein phosphatase-1, which may account for the effects of PKC-␣ on phospholamban phosphorylation (5) . This is in agreement with a recent report that heart PKC-␣-deficient mice are hypercontractile, whereas mice overexpressing PKC-␣ are hypocontractile (5) .
On the other hand, the specific rates of contraction and relaxation in hypertrophied and normal hearts were not different at normal or elevated extracellular Ca 2ϩ ; nevertheless, they were increased by captopril treatment. Because the slow Ca 2ϩ channels are the main mediators of extracellular Ca 2ϩ transport to the cytoplasm during the atrial action potential, we may speculate that the slow Ca 2ϩ channels are not directly affected during the compensated phase of eccentric cardiac hypertrophy; however, they may be activated by ACE inhibitor treatment through a PKC-dependent mechanism (35) .
In summary, we have shown that, in the aortocaval shuntoperated rat atrium, there is a decrease in the specific PTD that is overcome by the hypertrophy of the heart tissue to sustain normal cardiac function in the presence of a volume overload (compensated phase). ACE inhibitor treatment induces regression of eccentric cardiac hypertrophy. In addition, captopril improved peak tension, ϩdT/dt, and ϪdT/dt and increased PKC responsiveness of the contractile machinery in the shuntoperated rat heart. We suggest that ACE inhibition during eccentric cardiac hypertrophy produces a negative trophic and a positive inotropic effect through a PKC-dependent mechanism, inasmuch as PKC isozymes may have different and/or opposing effects in the heart (6).
